Certara

Publication

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…

CertaraJanuary 22, 2026

Webinar

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

CertaraJanuary 22, 2026

Press Coverage

The data fragmentation problem holding drug discovery back

Explore how fragmented data across the drug discovery DMTA cycle impedes progress, and discover how…

CertaraJanuary 21, 2026

Blog

Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus

Leveraging adaptive clinical trial designs in oncology can accelerate drug development, while following the FDA…

CertaraJanuary 16, 2026

Fact Sheet

Certara Solutions to Transform Drug Discovery and Development for Good

CertaraJanuary 15, 2026

Webinar

CHI ADC Webinar: Start Right-Finish Strong: Antibody-Drug Conjugate (ADC) Studies For Success

Danielle PillsburyJanuary 14, 2026

Webinar

Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies

CertaraJanuary 14, 2026

Blog

Transform PK/PD Workflows with Automation and Integration

Reduce delays and errors in PK/PD workflows. See where workflows stall, from data prep to…

CertaraJanuary 14, 2026

Webinar

Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data

CertaraJanuary 13, 2026

Announcement

Phoenix® PK/PD Software now Includes Generative AI pharmacokinetic (PK) Reports

New module transforms tables, figures and listings into draft PK reports saving scientists weeks of…

CertaraJanuary 12, 2026

© 2026 Certara. All Rights Reserved. | Legal | Privacy policy